新型植入式设备局灶皮层刺激与癫痫发作结局:两项前瞻性多中心单臂试验
汇总分析两项前瞻性多中心单臂试验(EASEE II 与 PIMIDES I),评估新型植入式设备(EASEE)行硬膜外局灶皮层刺激(FCS)辅助治疗成人药物难治性局灶性癫痫的安全性与疗效。33例植入设备,32例接受联合高频与类直流电刺激至8个月随访;刺激6个月时17/32例(53.1%)为应答者(发作频率较基线降低≥50%),中位发作减少52%(95% CI, 0.37%-0.76%; P < .001),未见设备或操作相关严重不良事件(0; 95% CI, 0%-10.58%)。
要点
- 刺激6个月时17/32例(53.1%)发作频率较基线降低≥50%。
- 中位发作减少52%(95% CI, 0.37%-0.76%; P < .001)。
- 未见设备或操作相关严重不良事件(0; 95% CI, 0%-10.58%)。
核心结论
- 两项非随机非对照试验的汇总分析提示,新型神经刺激设备行FCS与药物难治性局灶性癫痫患者发作频率的有效减少相关,可能为以单一癫痫灶为主的患者提供有前景的治疗选择。
研究设计与样本
- 研究为两项非随机非对照试验EASEE II与PIMIDES I的汇总分析,两项试验分别于2019年1月15日与2020年1月14日开始,于2021年7月28日结束。
- EASEE II与PIMIDES I为首次人体、前瞻性、单臂试验,评估期8个月,在7个欧洲癫痫中心连续入组药物难治性局灶性癫痫患者。
- 研究数据于2021年9月29日至2022年2月2日分析;6个德国与1个比利时研究中心共入组34例成人患者,其中33例(平均[SD]年龄34.6[13.5]岁;18例男性[54.5%])接受神经刺激设备植入。
主要发现
- 32例患者接受联合高频与类直流电刺激至少至植入后8个月随访。
- 刺激6个月后,17/32例(53.1%)为治疗应答者,发作频率较基线降低至少50%,对应中位发作减少52%(95% CI, 0.37%-0.76%; P < .001)。
- 未报告设备或操作相关严重不良事件(0; 95% CI, 0%-10.58%)。
- 认知、情绪或整体生活质量未见显著改变。
局限性
- 原文结论指出,该汇总分析来自两项非随机非对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For the large population of people with drug-refractory epilepsy, alternative treatment approaches are needed. Clinical trial outcomes of a novel stimulation device, which is newly available in Europe for the treatment of patients with a predominant seizure focus, are reported for the first time. OBJECTIVE: To perform a pooled analysis of the results of 2 prospective, multicenter, single-arm trials, A Pilot Study to Assess the Feasibility of Neurostimulation With the EASEE System to Treat Medically Refractory Focal Epilepsy (EASEE II) and A Pilot Study to Assess the Feasibility of Patient-Controlled Neurostimulation With the EASEE System to Treat Medically Refractory Focal Epilepsy (PIMIDES I), assessing the safety and efficacy of epicranial focal cortex stimulation (FCS) with a novel implantable device (EASEE [Precisis]) as adjunctive treatment for adult patients with drug-refractory focal epilepsy. DESIGN, SETTING, AND PARTICIPANTS: This study was a pooled analysis of 2 nonrandomized uncontrolled trials, EASEE II and PIMIDES I, which began on January 15, 2019, and January 14, 2020, respectively, and ended on July 28, 2021. EASEE II and PIMIDES I were the first in-human, prospective, single-arm trials with an 8-month evaluation period. Patients were recruited at 7 European epilepsy centers. Consecutive participants with drug-refractory focal epilepsy were enrolled. Study data were analyzed from September 29, 2021, to February 2, 2022. INTERVENTIONS: After a 1-month prospective baseline period, patients were implanted with the neurostimulation device. After a 1-month postimplantation recovery period, unblinded FCS was activated using both high-frequency and direct current (DC)-like components performed via electrode arrays placed epicranially above the individual epileptic focus region. MAIN OUTCOMES AND MEASURES: Efficacy was prospectively assessed by the responder rate in the sixth month of stimulation compared with baseline; safety and additional end points were assessed after device implantation and during the stimulation period. RESULTS: Of the 34 adult patients enrolled at 6 German and 1 Belgian investigational site, 33 (mean [SD] age, 34.6 [13.5] years; 18 male patients [54.5%]) received the neurostimulation device implant. A total of 32 patients underwent combined high-frequency direct current-like stimulation at least until the 8-month postimplant follow-up visit. After 6 months of stimulation, 17 of 32 patients (53.1%) were responders to treatment with at least a 50% reduction in seizure frequency compared with baseline, corresponding to a significant median seizure reduction by 52% (95% CI, 0.37%-0.76%; P < .001). No device- or procedure-related serious adverse events were reported (0; 95% CI, 0%-10.58%). There were no significant alterations in cognition, mood, or overall quality of life. CONCLUSIONS AND RELEVANCE: Results of this pooled analysis of 2 nonrandomized uncontrolled trials suggest that FCS with a novel neurostimulation device was associated with an effective reduction in seizure frequency in patients with drug-refractory focal epilepsy and may offer a promising treatment option for patients with a predominant epileptic focus. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00015918 and DRKS00017833, respectively, and jointly under PROSPERO: CRD42021266440.
引用
- Schulze-Bonhage A, Hirsch M, Knake S, et al. Focal Cortex Stimulation With a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Single-Arm Trials. JAMA Neurol. 2023. PMID: 37010826. doi:10.1001/jamaneurol.2023.0066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。